We recently published a list of 15 Stocks That Took a Nosedive in January. In this article, we are going to take a look at ...

Viking Therapeutics announces its fourth-quarter financial results after Wednesday's closing bell. Here's a look at the ...

Shares of Viking Therapeutics (VKTX) slid 8% post-market after the biotech company issued its Q4 earnings report and a pipeline update. Read more here.

Viking held cash, cash equivalents and short-term investments of $903M, compared to $362M as of December 31, 2023. 2024 ...

Qualcomm generated earnings of $3.41 a share in the latest quarter, versus Wall Street’s estimate for $2.96.

Pre-earnings options volume in Viking Therapeutics (VKTX) is normal with calls leading puts 15:2. Implied volatility suggests the market is ...

Loop Capital initiated coverage on the cruise industry in a note Wednesday, issuing a Buy rating on Viking and Hold ratings ...

The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly ...

Market uncertainty makes investors nervous about investing in speculative industries. But Wall Street has high hopes for ...

Follow all the latest U.S. market action for Wednesday here as Big Tech stocks again come under pressure on capex concerns.

Failed to fetch dynamically imported module: https://sg.finance.yahoo.com/assets/_app/immutable/nodes/19.peAgyjew.js ...

Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...